Onconano Medicine, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2014-12-29
- Employees
- 11
- Market Cap
- -
- Website
- http://www.onconano.com
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- Conditions
- Lymphoma, Non-HodgkinFollicular LymphomaBladder CancerMetastatic CancerTumor RecurrenceUveal Melanoma, RecurrentCarcinoma in SituSkin CancerTumor, SolidTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06022029
- Locations
- ๐บ๐ธ
California Research Institute, Los Angeles, California, United States
๐บ๐ธBRCR Global, Tamarac, Florida, United States
๐บ๐ธGabrail Cancer Center Research, Canton, Ohio, United States
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
- Conditions
- Lung Cancer
- Interventions
- Procedure: Tumor resection surgery
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05048082
- Locations
- ๐บ๐ธ
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04950166
- Locations
- ๐บ๐ธ
The Ohio State University Wexner Medical Center / James Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธAHN Cancer Institute, West Penn Hospital, Pittsburgh, Pennsylvania, United States
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaProstate CancerBreast CancerColorectal CancerOvarian CancerNon-small Cell Lung CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- OncoNano Medicine, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03735680
- Locations
- ๐บ๐ธ
The University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธThe University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธThe University of Texas Southwestern Medical Center, Dallas, Texas, United States